PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

News

Review highlights benefits of PCSK9i therapy but notes barriers to access US NLA guidance for FH includes PCSK9 inhibitors and bempedoic acid PCSK9 inhibitors benefit high-risk patients with vulnerable plaques Evolocumab may improve gut health in patients with myocardial infarction FOURIER: Evolocumab cuts MACE risk in those with obesity and ASCVD American College of Cardiology emphasises PCSK9 inhibitor role for PAD in diabetes

Verve-102

A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730)

Study title/design: A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730) Trial NCT06164730 (Recruiting) Estimated primary completion: August 2026 Estimated study completion: August 2026 Aim To evaluate the safety and pharmacodynamic profile of VERVE-102 in patients with familial hypercholesterolaemia…

Posted on 31 July 2024 | Posted in Trials, Verve-102

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.